{
    "clinical_study": {
        "@rank": "18368", 
        "arm_group": [
            {
                "arm_group_label": "Perioperative", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery"
            }, 
            {
                "arm_group_label": "Preoperative", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether perioperative immunonutrition has\n      additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy."
        }, 
        "brief_title": "Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic Tumor", 
            "Bile Duct Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bile Duct Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators reported that perioperative immunonutrition had no additional effects\n      compared with preoperative immunonutrition in patients underwent colorectal surgery (Braga\n      M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid\n      supplementation improves the immunometabolic host response and outcome after colorectal\n      resection for cancer. Surgery. 2002; 132:805-14, PMID: 12464864). Object of this study is to\n      investigate the additional effects of perioperative immunonutrition on cell-mediated\n      immunity and incidence of infectious complication after pancreaticoduodenectomy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients undergoing pancreaticoduodenectomy\n\n        Exclusion Criteria:\n\n          -  age younger than 18 years old\n\n          -  ongoing infection\n\n          -  gastrointestinal obstruction\n\n          -  respiratory dysfunction\n\n          -  cardiac dysfunction\n\n          -  hepatic dysfunction\n\n          -  renal failure\n\n          -  history of recent immunosuppressive or immunological disease\n\n          -  preoperative evidence of widespread metastatic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969110", 
            "org_study_id": "AEPIPD"
        }, 
        "intervention": {
            "arm_group_label": [
                "Perioperative", 
                "Preoperative"
            ], 
            "description": "Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery", 
            "intervention_name": "Oral IMPACT", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Immunonutrition", 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "contact": {
                "email": "k-furukawa@umin.ac.jp", 
                "last_name": "Katsunori Furukawa, MD", 
                "phone": "+81-43-222-7171", 
                "phone_ext": "72235"
            }, 
            "facility": {
                "address": {
                    "city": "Chiba", 
                    "country": "Japan", 
                    "zip": "260-8670"
                }, 
                "name": "Chiba University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy", 
        "overall_contact": {
            "email": "k-furukawa@umin.ac.jp", 
            "last_name": "Katsunori Furukawa, MD", 
            "phone": "+81-43-222-7171", 
            "phone_ext": "72235"
        }, 
        "overall_contact_backup": {
            "email": "d-suzuki@umin.ac.jp", 
            "last_name": "Daisuke Suzuki, MD", 
            "phone": "+81-43-222-7171", 
            "phone_ext": "72234"
        }, 
        "overall_official": {
            "affiliation": "Chiba University", 
            "last_name": "Katsunori Furukawa, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "plasma resolvin E1, cell-mediated immunity", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chiba University", 
            "investigator_full_name": "Katsunori Furukawa", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "infectious complication rate", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "source": "Chiba University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiba University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}